Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Matthew D. Hellmann
ResearcherPublications, citations & collaboration network
Matthew D. Hellmann is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 813 works, 101,394 citations, an h-index of 118 and an i10-index of 273.
813
Works
101,394
Citations
118
h-index
273
i10-index
How has Matthew D. Hellmann's publication output changed over time?
ScholarIQpublication output · 2015–2019
Output grew0% over the shown period — from 2 works in 2015 to 2 in 2019.
2
1
3
4
2
20152016201720182019
What are the most-cited papers on Matthew D. Hellmann?
ScholarIQmost cited works
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J. Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa Ho, Martin L. Miller, Natasha Rekhtman, André L. Moreira, Fawzia K. Ibrahim, Cameron Bruggeman, Billel Gasmi, Roberta Zappasodi, Yuka Maeda, Chris Sander, Edward B. Garon, Taha Merghoub, Jedd D. Wolchok, Ton N. Schumacher, Timothy A. Chan
Science. 20157,996 Citations
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui, Natasha B. Leighl, Ani Sarkis Balmanoukian, Joseph P. Eder, Amita Patnaik, Charu Aggarwal, Matthew A. Gubens, Leora Horn, Enric Carcereny, Myung‐Ju Ahn, Enriqueta Felip, Jong-Seok Lee, Matthew D. Hellmann, Omid Hamid, Jonathan W. Goldman, Jean‐Charles Soria, Marisa Dolled‐Filhart, Ruth Z. Rutledge, Jin Zhang, Jared Lunceford, Reshma Rangwala, Gregory M. Lubiniecki, Charlotte Roach, Kenneth Emancipator, Leena Gandhi
New England Journal of Medicine. 20156,267 CitationsOPEN ACCESS
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
Bertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa, Connie P.M. Duong, Maryam Tidjani Alou, Romain Daillère, Aurélie Fluckiger, Meriem Messaoudene, Conrad Rauber, María Paula Roberti, Marine Fidelle, Caroline Flament, Vichnou Poirier-Colame, Paule Opolon, Christophe Klein, Kristina Iribarren, Laura Mondragón, Nicolas Jacquelot, Bo Qu, Gladys Ferrere, Céline Clémenson, Laura Mezquita, J. Remon Masip, Charles Naltet, Solenn Brosseau, Courèche Kaderbhaï, Corentin Richard, Hira Rizvi, Florence Levenez, Nathalie Galleron, Benoît Quinquis, Nicolas Pons, Bernhard Ryffel, Véronique Minard-Colin, Patrick Gonin, Jean‐Charles Soria, Éric Deutsch, Yohann Loriot, François Ghiringhelli, Gérard Zalcman, François Goldwasser, Bernard Escudier, Matthew D. Hellmann, Alexander Eggermont, Didier Raoult, Laurence Albigès, Guido Kroemer, Laurence Zitvogel
Science. 20175,556 Citations
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow, Robert Sidlow, Matthew D. Hellmann
New England Journal of Medicine. 20184,775 Citations
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert Samstein, Chung‐Han Lee, Alexander N. Shoushtari, Matthew D. Hellmann, Ronglai Shen, Yelena Y. Janjigian, David Barron, Ahmet Zehir, Emmet Jordan, Antonio Omuro, Thomas Kaley, Sviatoslav M. Kendall, Robert J. Motzer, A. Ari Hakimi, Martin H. Voss, Paul Russo, Jonathan E. Rosenberg, Gopa Iyer, Bernard H. Bochner, Dean F. Bajorin, Hikmat Al‐Ahmadie, Jamie E. Chaft, Charles M. Rudin, Gregory J. Riely, Shrujal S. Baxi, Alan L. Ho, Richard J. Wong, David G. Pfister, Jedd D. Wolchok, Christopher A. Barker, Philip H. Gutin, Cameron Brennan, Viviane Tabar, Ingo K. Mellinghoff, Lisa M. DeAngelis, Charlotte E. Ariyan, Nancy Y. Lee, William D. Tap, Mrinal M. Gounder, Sandra P. D’Angelo, Leonard B. Saltz, Zsofia K. Stadler, Howard I. Scher, José Baselga, Pedram Razavi, Christopher A. Klebanoff, Rona Yaeger, Neil H. Segal, Geoffrey Y. Ku, Ronald P. DeMatteo, Marc Ladanyi, Naiyer A. Rizvi, Michael F. Berger, Nadeem Riaz, David B. Solit, Timothy A. Chan, Luc G.T. Morris
S137905309. 20194,419 CitationsOPEN ACCESS
Related on ScholarIQ
Memorial Sloan Kettering Cancer Center
Institution
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Paper
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Paper
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
Paper
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Paper
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Paper